AbbVie’s newer immunology drugs are offsetting Humira’s decline, sending stock up 5%
AbbVie’s earnings topped estimates, and it offered an upbeat view of 2025.
What's Your Reaction?







Chatty News Dec 7, 2024 0 43
Chatty News Nov 18, 2024 0 40
Chatty News Nov 26, 2024 0 35
Chatty News Nov 20, 2024 0 34
Chatty News Dec 26, 2024 0 33
Chatty News Nov 18, 2024 0 21
Chatty News Nov 18, 2024 0 23
Chatty News Nov 18, 2024 0 23
Total Vote: 5
Yes